|
| Exchange Disseminated Time | | Jubilant Life Sciences Ltd has informed BSE that the Board of Directors of the Company in its meeting held May 07, 2013 inter alia, accorded its approval to constitute a committee to explore options and opportunities to raise debt for the Company, including by way of issue of foreign currency bonds and /or non-convertible debentures, or by any one or more or a combination of the above or otherwise, to be denominated in Indian rupees or foreign currency, as the case may be, to various eligible investors in or outside India, whether by way of a public offering or by way of a private placement, in the best interests of the Company and all its stakeholders, up to an amount not exceeding US $ 250 million for prepayment of the existing debt and other general corporate purposes without increasing the overall net debt levels of the Company. |
|
|